Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Omnibus Funding Bill Provides Provisions For Future Pandemic Preparedness

Executive Summary

As a part of the end-of year omnibus bill, BARDA and FDA received funding to boost US’s domestic manufacturing of biomedical devices to prepare for future pandemics.

You may also be interested in...



What Should Be Included In PAHPA's Reauthorization?

At the first meeting of the Capitol Hill steering committee on pandemic preparedness, experts weighed in on what they hope to see in PAHPA’s reauthorization.

Year-End Spending Bill Sets FDA 2023 Budget At $6.6B

In addition to higher spending, the omnibus package now before the US Congress also addresses dual submissions, cybersecurity, pandemic preparedness, and more.  

Diagnostics Reform Out As Congress Reaches Year-End Omnibus Compromise

A measure that would have moved diagnostics regulation under the US Food and Drug Administration has been culled from the year-end omnibus spending package.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT147542

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel